Veracyte Statistics
Total Valuation
Veracyte has a market cap or net worth of $2.47 billion. The enterprise value is $2.23 billion.
| Market Cap | 2.47B |
| Enterprise Value | 2.23B |
Important Dates
The next confirmed earnings date is Wednesday, May 7, 2025, after market close.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Veracyte has 77.94 million shares outstanding. The number of shares has increased by 7.60% in one year.
| Current Share Class | 77.94M |
| Shares Outstanding | 77.94M |
| Shares Change (YoY) | +7.60% |
| Shares Change (QoQ) | +1.84% |
| Owned by Insiders (%) | 0.49% |
| Owned by Institutions (%) | 102.06% |
| Float | 77.57M |
Valuation Ratios
The trailing PE ratio is 102.16 and the forward PE ratio is 26.54. Veracyte's PEG ratio is 1.11.
| PE Ratio | 102.16 |
| Forward PE | 26.54 |
| PS Ratio | 5.43 |
| Forward PS | 4.96 |
| PB Ratio | 2.09 |
| P/TBV Ratio | 7.53 |
| P/FCF Ratio | 38.69 |
| P/OCF Ratio | 32.87 |
| PEG Ratio | 1.11 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 44.39, with an EV/FCF ratio of 34.95.
| EV / Earnings | 92.38 |
| EV / Sales | 5.00 |
| EV / EBITDA | 44.39 |
| EV / EBIT | 83.27 |
| EV / FCF | 34.95 |
Financial Position
The company has a current ratio of 4.73, with a Debt / Equity ratio of 0.04.
| Current Ratio | 4.73 |
| Quick Ratio | 4.33 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 0.84 |
| Debt / FCF | 0.80 |
| Interest Coverage | 13,388.50 |
Financial Efficiency
Return on equity (ROE) is 2.17% and return on invested capital (ROIC) is 1.47%.
| Return on Equity (ROE) | 2.17% |
| Return on Assets (ROA) | 1.39% |
| Return on Invested Capital (ROIC) | 1.47% |
| Return on Capital Employed (ROCE) | 2.19% |
| Revenue Per Employee | $540,976 |
| Profits Per Employee | $29,294 |
| Employee Count | 824 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 7.18 |
Taxes
In the past 12 months, Veracyte has paid $1.61 million in taxes.
| Income Tax | 1.61M |
| Effective Tax Rate | 6.24% |
Stock Price Statistics
The stock price has increased by +64.32% in the last 52 weeks. The beta is 2.03, so Veracyte's price volatility has been higher than the market average.
| Beta (5Y) | 2.03 |
| 52-Week Price Change | +64.32% |
| 50-Day Moving Average | 32.66 |
| 200-Day Moving Average | 34.73 |
| Relative Strength Index (RSI) | 49.97 |
| Average Volume (20 Days) | 984,610 |
Short Selling Information
The latest short interest is 5.11 million, so 6.56% of the outstanding shares have been sold short.
| Short Interest | 5.11M |
| Short Previous Month | 4.17M |
| Short % of Shares Out | 6.56% |
| Short % of Float | 6.59% |
| Short Ratio (days to cover) | 5.02 |
Income Statement
In the last 12 months, Veracyte had revenue of $445.76 million and earned $24.14 million in profits. Earnings per share was $0.31.
| Revenue | 445.76M |
| Gross Profit | 309.70M |
| Operating Income | 26.78M |
| Pretax Income | -54.79M |
| Net Income | 24.14M |
| EBITDA | 50.24M |
| EBIT | 26.78M |
| Earnings Per Share (EPS) | $0.31 |
Balance Sheet
The company has $289.44 million in cash and $50.74 million in debt, giving a net cash position of $238.70 million or $3.06 per share.
| Cash & Cash Equivalents | 289.44M |
| Total Debt | 50.74M |
| Net Cash | 238.70M |
| Net Cash Per Share | $3.06 |
| Equity (Book Value) | 1.18B |
| Book Value Per Share | 15.12 |
| Working Capital | 293.63M |
Cash Flow
In the last 12 months, operating cash flow was $75.10 million and capital expenditures -$11.29 million, giving a free cash flow of $63.81 million.
| Operating Cash Flow | 75.10M |
| Capital Expenditures | -11.29M |
| Free Cash Flow | 63.81M |
| FCF Per Share | $0.82 |
Margins
Gross margin is 69.48%, with operating and profit margins of 6.01% and 5.41%.
| Gross Margin | 69.48% |
| Operating Margin | 6.01% |
| Pretax Margin | 5.78% |
| Profit Margin | 5.41% |
| EBITDA Margin | 11.27% |
| EBIT Margin | 6.01% |
| FCF Margin | 14.31% |
Dividends & Yields
Veracyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.60% |
| Shareholder Yield | -7.60% |
| Earnings Yield | 0.98% |
| FCF Yield | 2.58% |
Analyst Forecast
The average price target for Veracyte is $41.78, which is 31.67% higher than the current price. The consensus rating is "Buy".
| Price Target | $41.78 |
| Price Target Difference | 31.67% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 8.84% |
| EPS Growth Forecast (5Y) | 47.47% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Veracyte has an Altman Z-Score of 10.48 and a Piotroski F-Score of 7.
| Altman Z-Score | 10.48 |
| Piotroski F-Score | 7 |